Before coronary stents, balloon angioplasty was limited by arterial dissection, acute closure, Q-wave myocardial infarction (MI), a 5% risk for emergency coronary artery bypass graft surgery, the need for repeat procedures to treat restenosis, and sometimes procedural death. Coronary stents immediately reduced those major procedural complications. The current debates about asymptomatic periprocedural biomarker release, late lumen loss, and the anecdotal risk of very late stent thrombosis seem effete compared with prior percutaneous coronary intervention (PCI) challenges and present controversies about PCI or coronary artery bypass graft surgery for left main disease, multivessel disease, bifurcation lesions, and chronic total occlusion. Yet, the painstaking research in PCI that has gone into developing better stent platforms with thinner struts, polymers to coat bare-metal stents, and drugs to elute from those polymers has dramatically reduced the risk of restenosis and need for repeat procedures. It has also expanded the opportunity for PCI as a treatment option for many patients.
However, it has become very confusing for the clinician to digest the large evidence base and reach a conclusion about individual stent superiority with multiple comparison trials testing different patient groups, different clinical settings, different lesion types, and different stents. Registry reports, marketing, and personal biases contribute to the challenge. Compared with bare-metal stents, we know that drug-eluting stents (DES) significantly reduce risk for restenosis and repeat procedures (1, 2) . Although there appears to be a small increased risk for late stent thrombosis, there does not seem to be an increased risk for MI or death. An important question in interventional cardiology, then, is whether second-generation zotarolimus-eluting stents (ZES) or everolimus-eluting stents (EES) are associated with improved clinical outcomes compared with firstgeneration sirolimus-eluting stents (SES) or paclitaxeleluting stents (PES). To address this question, several DES comparative trials have been completed or are recruiting patients.
The ENDEAVOR III (Randomized Controlled Trial of the Medtronic Endeavor Drug-Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions) trial (3) was a prospective, multicenter, 3:1 randomized trial comparing the efficacy and safety of ZES (n ϭ 323) with SES (n ϭ 113) in low-risk elective PCI. Reference vessel diameters were 2.5 to 3.5 mm and lesion lengths were 14 to 27 mm. The primary endpoint of in-segment late lumen loss at 8 months was greater with ZES (0.34 Ϯ 0.44 mm vs. 0.13 Ϯ 0.32 mm, p Ͻ 0.001), as was the in-segment binary restenosis rate (11.7% vs. 4.3%, p ϭ 0.04). In-hospital major adverse cardiac events were less with ZES (0.6% vs. 3.5%, p ϭ 0.04) because of fewer non-Q-wave MI events, but 9-month target lesion revascularization rates were numerically greater (9.8% vs. 3.5%, p ϭ 0.4). Study limitations listed by the investigators included inadequate statistical power to examine clinical endpoints, a very small SES comparison group, and a single-blinded study design.
Over a 3-year follow-up period, the death or MI rate with ZES was lower than with SES (3.9% vs. 10.8%, p ϭ 0.28), target vessel revascularization rates were numerically greater (17.9% vs. 12.2%, p ϭ 0.23), and coronary artery bypass graft surgery rates were higher (3.5% vs. 0%, p ϭ 0.002) (4). Total medical costs were similar ($23,353 vs. $21,657, p ϭ 0.23), with a cost-effectiveness ratio of $57,002 per quality-adjusted life year for ZES.
In this issue of JACC: Cardiovascular Interventions, Kandzari et al. (5) reported the 5-year clinical outcomes from the ENDEAVOR III trial. Rates of death (5.2% vs. 13.0%, p ϭ 0.02) and MI (1.0 vs. 4.6%, p ϭ p ϭ 0.03) were lower with ZES, despite no difference in target lesion revascularization (8.1% vs. 6.5%, p ϭ 0.68), target vessel revascularization (16.9% vs. 13.0%, p ϭ 0.36), or stent thrombosis (0.7% vs. 0.9%, p ϭ 1.0) rates. The investigators concluded that significant differences in death, MI, and composite endpoints favor treatment with ZES, although they again acknowledged in the text that statistical power was limited and differences in survival were principally related to noncardiac causes.
The long-term clinical outcome results of this trial need to be considered in the context of the other comparative ZES trials and compared with the results of the EES trials (Table 1 ) (5-13). A superficial review suggests inconsistent benefit with ZES and more benefit with EES. However, the ZES trials mostly used SES as comparators, whereas the EES trials initially used PES as comparators. Pooled analyses have suggested that PES are associated with more adverse events than SES are (1,2), perhaps making them easier comparators. Importantly, the phosphorylcholine polymer used with the Endeavor ZES (Medtronic CardioVascular, Santa Rosa, California) in these trials has been changed in the Resolute ZES (Medtronic CardioVascular) (available in Europe) to the BioLinx tripolymer (Medtronic CardioVascular) to permit drug elution over several months instead of days. Comparing this new generation ZES with EES in 2,292 patients enrolled in the Resolute All Comers trial (14) , there were no differences at 12 months in rates of death (1.6% vs. 2.8%), MI (4.2% vs. 4.1%), target vessel revascularization (4.9% vs. 4.8%), or definite/probable stent thrombosis (1.6% vs. 0.7%).
So, maybe my DES is better than yours. Or maybe it isn't. Maybe it depends on patient and angiographic characteristics. Or maybe it doesn't. Maybe bare-metal stents are better for some patients. Anyway, research continues on developing better stent platforms, more biocompatible polymers with improved release kinetics, and improved antiproliferative agents (15) . Additionally, there are studies enrolling patients treated with bioabsorbable or polymer-free DES, bioabsorbable DES, and drug-eluting balloons. There will be incremental progress made, but the reductions in adverse clinical events with new devices will be quite small. Studies larger than this one will be needed to prove stent superiority when individual endpoint differences between stents can be Ͻ1%. 
